Mergers & Acquisitions
Pharmion acquires Cabrellis Pharmaceuticals, rights to amrubicin
Published in Clinical Trials Week, December 18th, 2006
Amrubicin has been approved in Japan since 2002, where it is marketed by Nippon Kayaku under the trade name Calsed for the treatment of SCLC and non-small cell lung cancer (NSCLC). Dainippon Sumitomo Pharmaceuticals, the original developer of amrubicin, licensed the Japanese marketing rights to Nippon Kayaku in January 2005, and the North America and EU rights to Cabrellis (then...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2006-12-18)
More Articles from Clinical Trials Week
- Drug Development
Seattle Genetics initiates phase 1 trial of SGN-35 in Hodgkin, other hematologic malignancies - Dupuytren Contracture
Auxilium Pharmaceuticals initiates phase III trials for AA4500 in hand condition - Alcoholism Clinical Trial
Reports on alcoholism clinical trial findings from University of Pennsylvania, Department of Psychiatry provide new insights - Angiogenesis
Studies from University of Pennsylvania yield new data on angiogenesis - Arthritis Clinical Trial
Researchers from Vanderbilt University describe findings in arthritis clinical trial - Breast Cancer Quality of Care
New breast cancer quality of care study findings have been reported from Stanford University - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
